<DOC>
	<DOC>NCT01967225</DOC>
	<brief_summary>The aim of this study is to see the safety and efficacy of BAY1192631 when it is used for the treatment of skin and soft tissue infections (SSTI) or SSTI-related bacteremia.</brief_summary>
	<brief_title>Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<criteria>Inclusion Criteria Suspected or confirmed Methicillinresistant Staphylococcus aureus(MRSA) infection Japanese Male and female patients aged 18 years or above Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection , with/without SSTI (skin and soft tissue infection)derived MRSA bacteremia suspected Having received any systemic antibacterial potentially effective against MRSA for &gt;/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for &gt;/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA. Moribund clinical condition such as death likely within the first 3 days of a study drug treatment History of significant allergy or intolerance to linezolid or BAY1192631 Known or suspected human immunodeficiency virus (HIV) infection with a CD4+ Tcell count &lt; 200/Î¼L Chronic treatment with immunosuppressive drugs Active tuberculosis or nontuberculous mycobacteriosis which need medical treatments Current or anticipated neutropenia with neutrophil count &lt; 1,000/ mm3 Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) &gt;/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with Child Pugh score &gt;/=10.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Methicillin Resistant Staphylococcus Aureus,</keyword>
	<keyword>Skin and soft tissue infection,</keyword>
	<keyword>Bacteremia,</keyword>
	<keyword>Tedizolid</keyword>
</DOC>